Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | YWHAG | P61981 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RGS12 | O14924 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127019 | 0.86 | GAA (0.68) | GAAALDH1A1GFERHSP90AB1NPC1 | |
| SCHEMBL30096935 | 0.86 | GAA (0.68) | GAAALDH1A1GFERHSP90AB1NPC1 | |
| SCHEMBL29446278 | 0.85 | GAA (0.72) | GAAALDH1A1GFERHSP90AB1CYP4F2 | |
| SCHEMBL1786183 | 0.85 | NPC1 (0.63) | GAAALDH1A1GFERHSP90AB1NPC1 | |
| SCHEMBL3668882 | 0.85 | GAA (0.72) | GAAALDH1A1GFERHSP90AB1CYP4F2 | |
| SCHEMBL1008790 | 0.84 | YWHAG (0.53) | GAAALDH1A1GFERNPC1RAB9A | |
| Methyl Alcohol SCHEMBL27946196 | 0.84 | GAA (0.70) | GAAALDH1A1GFERHSP90AB1CYP4F2 | |
| SCHEMBL27972225 | 0.83 | APP (0.51) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL8146212 | 0.82 | GAA (0.63) | GAAALDH1A1GFERHSP90AB1NPC1 | |
| SCHEMBL14531746 | 0.81 | GAA (0.61) | GAAALDH1A1GFERHSP90AB1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101296914-B | Derivatives with PPAR agonist activity | SHIONOGI & CO | 2012-07-18 | — | — | CN | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-7781469-B2 | Arylacetate derivatives having isoxazole skeleton | SHIONOGI & CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090062531-A1 | Arylacetate Derivatives Having Isoxazole Skeleton | SHIONOGI & CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| CN-101296914-A | Derivatives with PPAR agonist activity | SHIONOGI & CO (JP) | 2008-10-29 | — | — | CN | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1887000-A1 | ARYLACETATE DERIVATIVE HAVING ISOXAZOLE SKELETON | Shionogi Co., Ltd. (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | GAA 4712/4885ALDH1A1 1821/4885GFER 2758/4885 |
| US-20090062531-A1 | Arylacetate Derivatives Having Isoxazole Skeleton | CYP2A7, CYP4X1, HAX1 | GAA 2743/4885ALDH1A1 877/4885GFER 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.